Testing for carcinoid syndrome typically starts with a urine or blood test that measures a chemical your body produces when a neuroendocrine tumor releases excess serotonin. The most established first-line test is the 24-hour urine 5-HIAA collection, which has a specificity of 97%, meaning false positives are rare. From there, doctors use imaging scans to locate the tumor and a biopsy to confirm the diagnosis and determine how aggressive it is.
The 24-Hour Urine 5-HIAA Test
Carcinoid tumors produce serotonin, and your body breaks serotonin down into a byproduct called 5-HIAA, which exits through urine. Measuring the amount of 5-HIAA in a full day’s worth of urine is the cornerstone diagnostic test for carcinoid syndrome. You’ll collect all urine over a 24-hour period into a special container provided by the lab, then return it for analysis.
The standard cutoff for a normal result is 50 μmol per 24 hours. At that threshold, the test catches essentially all active cases of carcinoid syndrome, though it can sometimes flag people who don’t actually have it (specificity around 69% at that cutoff). When researchers adjusted the cutoff slightly higher to 65 μmol in patients not already on treatment, the test maintained a sensitivity of about 95% while improving specificity to roughly 81%. Your doctor will interpret your result in context rather than relying on a single number.
The main drawback is practical: collecting every drop of urine for a full 24 hours is inconvenient and easy to do incorrectly. Incomplete collections are a common source of inaccurate results.
Blood-Based Alternatives
A fasting blood draw measuring plasma 5-HIAA is an increasingly used alternative. Research comparing the two approaches in over 100 patients with neuroendocrine tumors found that fasting plasma 5-HIAA values correlated strongly with the 24-hour urine results and provided essentially identical clinical information. For many patients, a single blood draw is far more practical than a day-long urine collection.
Doctors also commonly order a blood test for chromogranin A (CgA), a protein released by neuroendocrine cells. CgA is useful as a general marker for neuroendocrine tumors, but it’s less specific to carcinoid syndrome. Kidney problems can elevate CgA levels because the body clears it more slowly, and levels in non-cancerous conditions can reach into the hundreds of nanograms per milliliter. Cancer-related levels, by contrast, tend to climb into the thousands.
Foods and Medications That Skew Results
Several common foods naturally contain serotonin or related compounds and will artificially inflate your 5-HIAA results. You’ll need to avoid these for at least 72 hours before and during your urine collection:
- Fruits: bananas, pineapple, plums, plantain, avocados
- Vegetables: tomatoes, eggplant
- Nuts: walnuts
Medications can also interfere. Acetaminophen, caffeine, cough suppressants containing guaifenesin, naproxen, nicotine, and certain sedatives like diazepam can all push 5-HIAA readings higher than they should be. Your ordering physician should review your medication list before the test.
If your doctor orders a chromogranin A test, proton pump inhibitors (PPIs) like omeprazole are a major concern. CgA levels rise significantly after just five days of PPI use. The good news is that stopping PPIs for five days before the blood draw is typically enough to bring levels back down. Your doctor may ask you to pause these medications briefly before testing.
Imaging to Locate the Tumor
Once blood or urine tests suggest carcinoid syndrome, the next step is finding the tumor and any sites where it may have spread. Most carcinoid tumors display somatostatin receptors on their surface, which specialized imaging scans can detect.
The older approach, known as an octreotide scan, uses a radioactive tracer that binds to these receptors. It requires multiple visits over two to three days, has relatively low spatial resolution, and can be hard to interpret because normal organs also absorb the tracer. A newer scan, Gallium-68 DOTATATE PET/CT, works on the same principle but is completed in a single day, produces sharper images, and detects more lesions. Pooled research puts its sensitivity at about 90%, compared to 83% for the older octreotide scan. Multiple studies have shown it picks up tumors, particularly small bowel primaries and liver metastases, that the older scan misses entirely. It is rapidly becoming the standard imaging choice for neuroendocrine tumors.
Standard CT and MRI scans still play a role, particularly for measuring tumor size and planning surgery, but they don’t reveal whether a tumor expresses the receptors that guide treatment decisions.
Biopsy and Tumor Grading
A tissue sample confirms the diagnosis and tells your medical team how fast the tumor is growing. Pathologists examine the biopsy under a microscope and assign a grade based on two measurements: how many cells are actively dividing (the mitotic count) and the percentage of cells staining positive for a proliferation marker called Ki-67.
The grading system works like this:
- Grade 1 (low grade): fewer than 2 dividing cells per microscopic field, Ki-67 below 3%. These are slow-growing tumors, the classic “carcinoid.”
- Grade 2 (intermediate): 2 to 20 dividing cells, Ki-67 between 3% and 20%. Still well-differentiated but growing faster.
- Grade 3 (high grade): more than 20 dividing cells, Ki-67 above 20%. These are aggressive, poorly differentiated cancers classified as neuroendocrine carcinomas rather than typical carcinoids.
The grade directly influences treatment planning. Most tumors causing carcinoid syndrome fall into Grade 1 or 2, since the syndrome itself is driven by a functioning, serotonin-producing tumor rather than a rapidly dividing one.
Screening for Carcinoid Heart Disease
One of the most serious complications of carcinoid syndrome is damage to the heart valves, caused by prolonged serotonin exposure. Up to half of patients with carcinoid syndrome develop some degree of heart involvement over time, so screening is a routine part of the workup.
A blood test measuring NT-proBNP, a protein released when the heart is under strain, serves as an effective screening tool. At a cutoff of 260 pg/ml, this test has a sensitivity of 92% and specificity of 91% for detecting carcinoid heart disease. Patients without heart involvement typically show levels around 101 pg/ml, while those with valve damage average around 1,149 pg/ml. The negative predictive value is 98%, meaning a result below the cutoff makes heart involvement very unlikely.
If NT-proBNP comes back elevated, an echocardiogram (heart ultrasound) is the next step to directly visualize valve thickening or dysfunction. Regular echocardiograms are recommended for anyone with confirmed carcinoid syndrome, even if the initial NT-proBNP is normal, because heart disease can develop gradually as the condition progresses.